Sign in Subscribe
BioMed

🧬 BioMed Pulse · 2026-07-19 02:01 UTC

BIOMED PULSE

Saturday, July 19, 2026 | Your daily briefing on longevity, viruses, and new cures

⚡ TL;DR

The Bundibugyo virus Ebola outbreak in DRC and Uganda has now reached 2,124 confirmed cases and 828 deaths as of July 15, 2026, making it the dominant global health emergency. [1] Alongside this, WHO released landmark dementia-prevention guidelines estimating up to 45% of dementia risk is preventable, offering rare good news in an otherwise sobering week. [2]

🦠 OUTBREAKS & VIRUSES

EBOLA BUNDIBUGYO VIRUS - DRC AND UGANDA (PHEIC)

  • As of July 15, 2026, 2,124 confirmed cases and 828 deaths have been reported from DRC, with cross-border transmission continuing in Uganda. [1]
  • The case fatality ratio among confirmed cases stands at approximately 39%, with sustained community transmission driving case count increases week over week. [1]
  • WHO's PARTNERS clinical trial, opened July 2, 2026, is now enrolling patients in DRC to evaluate the first candidate treatments specifically for Bundibugyo virus disease. [3]
  • WHO added the first molecular diagnostic test for Bundibugyo virus (BDBV) to its Emergency Use Listing on July 2, 2026, enabling rapid genetic confirmation from blood samples. [4]
  • Africa CDC and WHO launched a joint continental Ebola response plan on June 5, 2026, seeking to raise USD 518 million to support African country preparedness. [5]
  • WHO issued its first comprehensive filovirus clinical management guidelines on June 17, 2026, covering all Ebola species and Marburg virus. [6]
  • Enhanced Ebola airport screening is active at Washington-Dulles International Airport and has expanded to Atlanta Hartsfield-Jackson. [7][8]

ANDES HANTAVIRUS - M/V HONDIUS CRUISE SHIP (MULTI-COUNTRY)

  • The fifth WHO Disease Outbreak News report, published July 2, 2026, confirmed ongoing Andes hantavirus (ANDV) cases linked to passengers of the cruise ship M/V Hondius, originally reported May 2, 2026. [9]
  • ANDV causes hantavirus cardiopulmonary syndrome, a severe respiratory illness with high fatality; the cluster spans multiple countries via disembarked passengers. [10][9]
  • CDC provided a separate hantavirus response update on June 24, 2026, reflecting continued U.S. federal engagement.

CYCLOSPORIASIS - UNITED STATES

  • CDC held a Cyclosporiasis response update briefing on July 14, 2026, signaling an active domestic investigation into Cyclospora infections.

NIPAH VIRUS - INDIA

  • On June 11, 2026, Kerala State Health Department confirmed one adult male case of Nipah virus (NiV) infection in Kozhikode district; the patient developed neurological symptoms on May 30, 2026.
  • Kozhikode has been the epicenter of prior Indian NiV outbreaks; contact tracing is standard given NiV's case fatality rate of 40-75%.

WEST NILE VIRUS - UNITED STATES

  • CDC reported an early and record-setting West Nile virus season as of July 1, 2026, urging Americans to use mosquito repellents throughout the summer.

YELLOW FEVER - GLOBAL

  • From January 1 to May 26, 2026, six countries reported 79 human yellow fever infections; transmission that began surging in the Americas in 2025 continued into 2026.

AVIAN INFLUENZA A(H9N2) - ITALY

  • Italy notified WHO in March 2026 of one adult male case of H9N2 confirmed by next-generation sequencing after the patient returned from Senegal, representing a sporadic zoonotic spillover event.

MEASLES - BANGLADESH

  • As of early April 2026, Bangladesh reported 19,161 suspected measles cases across 58 of 64 districts, with 2,897 laboratory-confirmed infections spanning all eight administrative divisions.

MPOX RECOMBINANT VIRUS - GLOBAL

  • WHO reported in February 2026 two cases of a recombinant monkeypox virus (MPXV) strain combining genomic elements of clade Ib and clade IIb, a natural but concerning genetic exchange event.

E. COLI - FROZEN BLUEBERRIES

  • CDC issued a food safety alert on July 7, 2026, warning consumers not to eat recalled frozen blueberries linked to an E. coli outbreak; product recall is in effect.

🧬 LONGEVITY & AGING

DEMENTIA PREVENTION - WHO GUIDELINES

  • WHO released updated dementia-prevention guidelines on July 15, 2026, concluding that up to 45% of dementia risk could be prevented or delayed through evidence-based interventions across the life course. [2]
  • The guidelines provide countries with ranked, actionable recommendations targeting modifiable risk factors including hypertension, physical inactivity, social isolation, and hearing loss. [2]

NAD-PLUS HOMEOSTASIS AND BONE AGING

  • A Europe PMC study in Bioactive Materials described a senescent metabolism-modulating hierarchical scaffold that restores NAD-plus homeostasis and redox balance in aged bone tissue, improving repair outcomes.
  • Declining NAD-plus in senescent cells impairs energy metabolism and fuels the chronic inflammation associated with poor fracture healing in older adults.

COLLAGEN XVII AND SKIN PHOTOAGING

  • Recombinant human collagen XVII was shown to protect epidermal stem cells from blue light-induced photoaging by downregulating the Notch signaling pathway in a study published July 16, 2026.
  • Epidermal stem cell exhaustion is a hallmark of skin aging; this mechanism suggests collagen XVII supplementation or topical delivery as a potential anti-photoaging strategy.

TAU, EMERIN, AND NEURONAL AGING

  • Research published July 7, 2026 in Nucleus found that the nuclear membrane protein emerin is elevated in response to mechanical stress and links nuclear mechanotransduction to tau-induced cytoskeletal remodeling in neurons.
  • Tau pathology is central to Alzheimer's disease and several other tauopathies; this emerin-tau axis may represent a new upstream therapeutic target.

KAEMPFEROL FROM MORINGA AND LIFESPAN

  • A Toxicology Reports study published June 25, 2026, found kaempferol isolated from Moringa oleifera increased longevity and reduced efavirenz-induced functional senescence in Drosophila melanogaster.
  • Efavirenz is an antiretroviral drug associated with mitochondrial toxicity; kaempferol's anti-senescence effect was linked to antioxidant and anti-inflammatory pathways in this insect model.

DELIRIUM AS A BRIDGE TO DEMENTIA

  • Two linked Lancet Healthy Longevity commentaries propose that delirium during severe infections may be a mechanistic missing link between acute illness and long-term cognitive decline and dementia in older adults.
  • The hypothesis centers on neuroinflammatory cascades triggered during delirium that accelerate tau and amyloid pathology in vulnerable brains.

HYPERTENSION AND FRAILTY IN OLDER ADULTS

  • A letter published in Blood Pressure journal, July 7, 2026, highlights associations between hypertension and frailty in middle-aged and older Indian adults from the Longitudinal Ageing Study in India (LASI).
  • Controlling blood pressure in midlife could simultaneously reduce frailty burden, a compounding risk factor for mortality and disability.

DEMENTIA PREVENTION READINESS

  • A Lancet Healthy Longevity perspective called for healthcare systems to prepare now for a coming "dementia prevention era," emphasizing that equity and real-world implementation gaps must be addressed before interventions reach scale.

PHYSICAL ACTIVITY RESTRICTION AND BRAIN HEALTH

  • An ecological panel study across Japan's 47 prefectures (2013-2022) found that structural physical activity restrictions were associated with increased cerebrovascular and diabetes mortality and greater long-term care intensity, with a COVID-19 counterfactual analysis reinforcing the causal estimate.

💊 NEW CURES & APPROVALS

  • RETEVMO (selpercatinib), sponsored by Eli Lilly and Co, received a supplemental approval (NDA213246 and NDA218160), a RET kinase inhibitor used in RET-altered non-small cell lung cancer, thyroid cancer, and other solid tumors.
  • REVTORPYK (gedatolisib), sponsored by Celcuity Inc., received an original approval (NDA219908) as a PI3K/mTOR dual inhibitor for oncology indications.
  • ENLICITIDE (enlicitide chloride), sponsored by Merck Sharp and Dohme LLC, received an original approval (NDA220848), representing a new molecular entity in the FDA pipeline.
  • REPATHA (evolocumab), sponsored by Amgen Inc., received a supplemental approval (BLA125522); evolocumab is a PCSK9 inhibitor indicated to lower LDL cholesterol and reduce cardiovascular events.
  • STELARA (ustekinumab), sponsored by Centocor Ortho Biotech Inc., received a supplemental approval (BLA125261); ustekinumab is an IL-12/IL-23 antagonist used in plaque psoriasis, psoriatic arthritis, and inflammatory bowel disease.
  • Afatinib dimaleate (EGFR inhibitor) received original generic approvals from both Hetero Labs Ltd V (ANDA210750) and Apotex (ANDA210725), expanding affordable access for EGFR-mutant non-small cell lung cancer patients.

🧪 CLINICAL TRIALS

  • A new Phase I/II trial (NCT07667400, registered July 17, 2026) is studying docetaxel combined with SX-682, a CXCR1/2 inhibitor, in recurrent or metastatic head and neck squamous cell carcinoma, salivary gland carcinoma, and advanced prostate cancer, targeting immunosuppressive tumor microenvironments.
  • Trial NCT07686380 (registered July 17, 2026) is evaluating IL-15 superagonist N-803 alone or combined with the prostate cancer vaccine ETBX-071 in biochemically recurrent prostate cancer following stereotactic body radiation therapy, enrolling men with rising PSA levels post-radiation.
  • Trial NCT05705648 is investigating dietary oil supplementation for long COVID brain fog symptoms in adults aged 22-50, examining both natural course and nutritional intervention effects on cognitive complaints.
  • Trial NCT06513962 (Phase III) is comparing triptorelin versus no triptorelin for prevention of chemotherapy-induced ovarian damage in adolescents and young adults with cancer receiving alkylating agents.
  • Trial NCT06615973 is screening for social determinants of health and cognitive function in stroke survivors, noting that more than 70% of stroke survivors develop mental impairment or dementia.
  • Trial NCT07704333 is assessing the pharmacokinetics of [18F]-fluorocellobiose, a novel PET imaging tracer, for detecting invasive mold infections in healthy volunteers and immunocompromised patients, addressing the estimated 3.8 million annual deaths linked to fungal disease.
  • Trial NCT06948110 is deciphering the genetic architecture of autoimmune diseases with a focus on understudied Indigenous populations from North and South America, aiming to broaden genomic representation.

📢 PUBLIC HEALTH

LISTERIA OUTBREAK - DELI MEATS

  • CDC opened a new Listeria monocytogenes investigation on July 19, 2024, linked to meats sliced at deli counters across multiple states; consumers are urged to check recalled product lists.

CANCER BURDEN - WHO PROJECTION

  • WHO warned on July 8, 2026, that new global cancer cases are projected to nearly double by 2050 from the current 20.6 million annual cases; over 26,000 people die of cancer every day worldwide.

GLOBAL CHILDHOOD IMMUNIZATION

  • A joint WHO-UNICEF report (July 15, 2026) found that in 2025, 90% of infants globally received at least one dose of DTP vaccine, and 85% completed the full three-dose series, representing incremental but incomplete progress amid conflict and vaccine hesitancy.

EL SALVADOR ELIMINATES TRACHOMA

  • WHO validated El Salvador on July 13, 2026, as having eliminated trachoma as a public health problem; trachoma remains the world's leading infectious cause of blindness.

HEALTHCARE-ASSOCIATED INFECTIONS DECLINING

  • CDC data published July 15, 2026, show a decline in hospital-acquired infections in 2023, reflecting improved patient safety practices across U.S. healthcare facilities.

INFANT FORMULA CONTAMINATION WARNING

  • WHO issued a multi-country food safety alert in March 2026 after cereulide toxin (produced by Bacillus cereus) was detected in infant formula and other products; the source was traced to contaminated arachidonic acid (ARA) oil used as an ingredient.

UNSAFE FOOD BURDEN

  • New WHO estimates released June 3, 2026, calculate that unsafe food causes 866 million illnesses and 1.5 million deaths annually, with children under five facing nearly three times the illness risk of older individuals.

TOBACCO AND LIVER DISEASE

  • A Europe PMC study quantified the global burden of metabolic dysfunction-associated steatotic liver disease (MASLD) attributable to tobacco from 1990 to 2023, with projections to 2038 showing tobacco remains a significant and modifiable driver of liver disease worldwide.

This briefing is informational only and does not constitute medical advice. Sources: WHO, CDC, openFDA, ClinicalTrials.gov, Europe PMC/PubMed.

📎 Sources

  1. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
  2. New WHO guidelines: up to 45% of dementia risk could be preven… — WHO News
  3. Patient enrolment begins in a scientific trial to identify the… — WHO News
  4. WHO adds first diagnostic test for Ebola Bundibugyo virus to i… — WHO News
  5. Africa CDC and WHO launch joint continental Ebola response plan — WHO News
  6. WHO issues comprehensive guidelines on filovirus disease, incl… — WHO News
  7. Enhanced Ebola Airport Screening Begins at Washington-Dulles I… — CDC Newsroom
  8. Enhanced Ebola Airport Screening Expands to Atlanta — CDC Newsroom
  9. Hantavirus outbreak linked to cruise ship travel, Multi-locations — WHO Disease Outbreak News
  10. Hantavirus cluster linked to cruise ship travel, Multi-country — WHO Disease Outbreak News

Curated from official sources — WHO/CDC/ECDC/openFDA/ClinicalTrials.gov/Europe PMC. Informational only — not medical advice.
Serial 20260719-02-v32 · 2026-07-19 02:01 UTC · pulse.uzylab.com

Read next